Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cx601

- PMLiVE

Takeda’s obesity drug Contrave launches in US

Clears cardiovascular safety hurdle to be third new weight-loss drug in recent months

- PMLiVE

Takeda appoints head of vaccines development

John Boslego will succeed Ralf Clemens

- PMLiVE

Takeda opens new UK office in High Wycombe

Hopes move to larger premises will help expand business

- PMLiVE

Takeda loses in lawsuit claiming cancer link to Actos

Ordered to compensate woman who claims drug gave her bladder cancer

- PMLiVE

Humira gets FDA nod for paediatric Crohn’s disease

Can be used as treatment for patients as young as six

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

TiGenix appoints Dr Marie Paule Richard

She takes on role as chief medical officer and brings experience from Aicuris and Crucell

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

- PMLiVE

Takeda drops prostate cancer drug in phase III

Suffers another late-stage pipeline blow as orteronel disappoints

- PMLiVE

Omontys terminal as Takeda switches off support

Japanese company ends anaemia treatment partnership with Affymax

EU flag

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links